BEST-CLI试验中专科差异对血管腔内实践模式与结局的影响
BEST-CLI试验比较了CLTI患者血管腔内治疗与开放手术,本研究分析参与专科(介入心脏病学、介入放射学、血管外科)的腔内实践模式和结局差异。血管外科治疗多数腔内患者且更多非裔美国人和3级肢体缺血者;介入心脏病学更多使用P2Y12抑制剂、氯吡格雷、双联抗血小板治疗、胫动脉治疗、斑块旋切、药物涂层球囊和药物洗脱支架;介入放射学MALE-死亡发生率较低,主要由死亡和重大血运重建较低驱动,但主要截肢无差异。
要点
- 血管外科治疗多数腔内患者,更多非裔美国人和3级肢体缺血者。
- 介入心脏病学更多使用P2Y12抑制剂、双联抗血小板、胫动脉治疗和斑块旋切等。
- 介入放射学MALE-死亡发生率较低,但主要截肢无差异。
核心结论
- BEST-CLI试验中介入心脏病学、介入放射学和血管外科的腔内实践模式存在显著差异。
- 介入放射学MALE-死亡、死亡和重大血运重建发生率低于介入心脏病学和血管外科,但主要截肢无差异。
研究设计与样本
- BEST-CLI试验的事后分析,纳入符合试验认证标准并接受腔内治疗的CLTI患者。
- 按介入心脏病学、介入放射学和血管外科分组,比较人口学和实践模式差异。
主要发现
- 血管外科治疗多数腔内患者,更多治疗非裔美国人和3级肢体缺血者(P = .016)。
- 介入心脏病学更多治疗西班牙裔,并使用P2Y12抑制剂(P = .005)、氯吡格雷(P = .021)和双联抗血小板治疗(P = .002)。
- 介入心脏病学更多治疗胫动脉(P = .007),使用斑块旋切(P < .001)、药物涂层球囊(P < .001)和药物洗脱支架(P < .001)。
- 介入放射学MALE-死亡低于介入心脏病学(RR, 2.34; 95%CI, 1.45-3.77; P = .0005)和血管外科(RR, 0.54; 95%CI, 0.37-0.77; P = .0007)。
- 介入放射学死亡低于介入心脏病学(RR, 3.16; 95%CI, 1.80-45.55; P < .0001)和血管外科(RR, 0.44; 95%CI, 0.28-0.70; P = .0005)。
关键数值与推荐
- MALE-死亡介入心脏病学 vs 介入放射学:RR, 2.34; 95%CI, 1.45-3.77; P = .0005。
- MALE-死亡介入放射学 vs 血管外科:RR, 0.54; 95%CI, 0.37-0.77; P = .0007。
- 死亡介入心脏病学 vs 介入放射学:RR, 3.16; 95%CI, 1.80-45.55; P < .0001。
- 死亡介入放射学 vs 血管外科:RR, 0.44; 95%CI, 0.28-0.70; P = .0005。
- 重大血运重建介入放射学 vs 血管外科:RR, 0.55; 95%CI, 0.32-0.96; P = .034。
临床怎么用
- 专科间实践模式差异显著,患者选择和器械使用不同。
- 介入放射学MALE-死亡和死亡较低,但主要截肢无差异,需结合患者特征解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Best Endovascular vs best Surgical Therapy in Patients with Chronic Limb-threatening Ischemia (CLTI) (BEST-CLI) trial was a multi-specialty trial that compared endovascular therapy with open surgery in patients with CLTI. We evaluated differences in endovascular practice patterns and outcomes among participating specialties. METHODS: All patients who underwent endovascular therapy performed by interventional cardiologists (ICs), interventional radiologists (IRs), and vascular surgeons (VSs) who met credentialing criteria in the trial were included in the analysis. Between-specialty group differences in demographics and practice patterns were evaluated using analysis of variance. The primary endpoint was major adverse limb events (MALE) and death (MALE-death); subcomponents of major revascularization, above-ankle amputation, and death were also examined. RESULTS: VSs treated the majority of the patients in the endovascular arm of BEST-CLI and more frequently treated patients of African-American descent and those with grade 3 limb ischemia (P = .016). ICs more frequently treated patients of Hispanic ethnicity, and utilized P2Y12 inhibitors (P = .005), clopidogrel (P = .021), and dual antiplatelet therapy (P = .002) compared with IRs and VSs. ICs also more often treated tibial arteries (P = .007), and utilized atherectomy (P < .001), drug-coated balloon angioplasty (P < .001), and drug-eluting stents (P < .001). There was no difference in endovascular technical failure between the groups. Over the course of follow-up, IRs had a lower incidence of MALE-death compared with ICs (IC vs IR: rate ratio [RR], 2.34; 95% confidence interval [CI], 1.45-3.77; P = .0005) and VS (IR vs VS: RR, 0.54; 95% CI, 0.37-0.77; P = .0007). This was largely driven by a lower incidence of death (IC vs IR: RR, 3.16; 95% CI, 1.80-45.55; P < .0001; IR vs VS: RR, 0.44; 95% CI, 0.28-0.70; P = .0005) and major revascularization (IC vs IR: RR, 1.56; 95% CI, 0.67-3.63; P = .30; IR vs VS: RR, 0.55; 95% CI, 0.32-0.96; P = .034). There was no difference in above-ankle amputation between the groups (IC vs IR: RR, 1.55; 95% CI, 0.74-3.22; P = .24; IC vs VS: RR, 1.12; 95% CI, 0.60-2.07; P = .72, IR vs VS: RR, 0.72; 95% CI, 0.42-1.24; P = .24). CONCLUSIONS: Significant differences in practice patterns were seen between ICs, IRs, and VSs in BEST-CLI. The majority of patients were enrolled by VSs. There was significant differences in severity of patient CLTI at presentation. Although IRs had a lower incidence of MALE-death, death, and major revascularization compared with ICs and VSs, there was no difference in major amputation between the specialties.
引用
- Powell RJ, Menard MT, Rosenfield K, et al. Influence of specialty on endovascular practice patterns and outcomes in the BEST-CLI Trial. J Vasc Surg. 2025. PMID: 41205838. doi:10.1016/j.jvs.2025.10.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。